Protalix BioTherapeutics Overview

Protalix BioTherapeutics Operating Income

Operating Income for PLX.

Quarterly Operating Income

$21.15M

↓ 610.16% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$19.79M

↑ 327.64% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin